Browsing: achieved
Four years after pre-surgery treatment with a new combination of immune inhibitors, Nivolumab and Relatlimab, 87% of patients with Stadium…
Four years after pre-surgery treatment with a new combination of immune inhibitors, Nivolumab and Relatlimab, 87% of patients with Stadium…